MeSH D018358 - neuroendocrine tumors
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D017599:Neuroectodermal tumors
0 Companies
0 Drugs
Success rate
D018358:
Neuroendocrine tumors
D000237:Basophil adenoma
0 Companies
0 Drugs
Success rate
D000238:Chromophobe adenoma
0 Companies
0 Drugs
Success rate
D000239:Acidophil adenoma
0 Companies
0 Drugs
Success rate
D001079:Apudoma
0 Companies
0 Drugs
Success rate
D002276:Carcinoid tumor
D008545:Melanoma
D009442:Neurilemmoma
0 Companies
0 Drugs
Success rate
D010235:Paraganglioma
0 Companies
0 Drugs
Success rate
D018278:Neuroendocrine carcinoma
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Accord Healthcare | Sunitinib | Sunitinib Accord | 2021-02-11 | |||
| Advanced Accelerator Applications | Lutetium (177lu) oxodotreotide, Lutetium lu 177 dotatate | Lutathera | 2017-09-26 | |||
| Edotreotide | SomaKit TOC | 2016-12-08 | ||||
| Cipla | Lanreotide | Lanreotide | 2021-12-17 | |||
| CP Pharmaceuticals International CV | Sunitinib | Sutent | 2006-01-26 | |||
| Dr Reddys Laboratories | Sunitinib | Sunitinib | 2022-04-11 | |||
| Eugia Pharma Specialties | Sunitinib | Sunitinib | 2024-03-14 | |||
| Ipsen | Lanreotide | Somatuline Depot | 2007-08-30 | |||
| Merck Sharp & Dohme | Avelumab | Bavencio | 2017-09-18 | |||
| Mylan | Sunitinib | Sunitinib | 2021-12-06 | |||
| NATCO Pharma | Sunitinib | Sunitinib | 2023-10-24 |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
74%40/54
Phase 2
34%30/89
Phase 3
25%9/36
Approved: 5Overall Success rate: 6%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use